Novo's Wegovy Pill Hits 18,410 Prescriptions in First Week Post-Launch

• The pill generated 18,410 prescriptions in its first full week, outpacing other GLP-1 drug launches according to Guggenheim analysts
• Investors are watching prescription data closely to gauge Novo Nordisk's competitive position against rival Eli Lilly in the weight-loss market
• The launch represents Novo's attempt to press its first-mover advantage in the oral GLP-1 weight-loss segment

Summary

Novo Nordisk's oral Wegovy pill recorded 18,410 U.S. prescriptions during its first full week following launch, according to IQVIA data. The strong debut is being closely monitored by investors as the Danish pharmaceutical giant seeks to maintain its first-mover advantage over competitor Eli Lilly in the lucrative weight-loss drug market.

Key Performance Metrics:

• 18,410 prescriptions in week one post-launch
• Guggenheim analysts noted the figures are "tracking ahead of other GLP-1 launches," indicating stronger-than-expected market reception

Market Context:

The prescription data is critical for assessing Novo Nordisk's competitive positioning in the rapidly growing weight-loss medication sector. GLP-1 drugs (glucagon-like peptide-1 receptor agonists) have become a major pharmaceutical battleground, with Novo Nordisk and Eli Lilly competing for market dominance.

Implications:

The robust first-week performance suggests strong physician and patient interest in the oral formulation of Wegovy, which could provide a more convenient alternative to injectable versions. The pill format may appeal to patients who prefer oral medication over injections, potentially expanding the total addressable market.

The early prescription numbers exceed typical GLP-1 launch trajectories, positioning Novo Nordisk favorably as it defends its market share against Eli Lilly's competing products. Investors will continue tracking weekly prescription data to assess sustained demand and market penetration in the coming months.

This launch represents a significant milestone in the competitive weight-loss pharmaceutical market, estimated to be worth billions annually as obesity treatment demand continues to surge.